SK Plasma Core Indonesia, part of South Korea’s SK Group, is a biopharmaceutical company specializing in plasma-derived medicines that treat hemophilia, immune deficiencies, and severe bleeding disorders. In partnership with Indonesia’s Ministry of Health, SK Plasma is establishing a plasma fractionation plant in Indonesia to secure local production of life-saving treatments. More than a single project, SK Plasma is committed to building a sustainable presence by transferring expertise, supporting plasma donation programs, and ensuring reliable access to vital medicines made from plasma donated by Indonesians, for Indonesians.
SK Plasma Core Indonesia, part of South Korea’s SK Group, is a biopharmaceutical company specializing in plasma-derived medicines that treat hemophilia, immune deficiencies, and severe bleeding disorders. In partnership with Indonesia’s Ministry of Health, SK Plasma is establishing a plasma fractionation plant in Indonesia to secure local production of life-saving treatments. More than a single project, SK Plasma is committed to building a sustainable presence by transferring expertise, supporting plasma donation programs, and ensuring reliable access to vital medicines made from plasma donated by Indonesians, for Indonesians.
SK Plasma Core Indonesia, part of South Korea’s SK Group, is a biopharmaceutical company specializing in plasma-derived medicines that treat hemophilia, immune deficiencies, and severe bleeding disorders. In partnership with Indonesia’s Ministry of Health, SK Plasma is establishing a plasma fractionation plant in Indonesia to secure local production of life-saving treatments. More than a single project, SK Plasma is committed to building a sustainable presence by transferring expertise, supporting plasma donation programs, and ensuring reliable access to vital medicines made from plasma donated by Indonesians, for Indonesians.